What will the approximate medical insurance price of nintedanib be in 2025?
In mainland China, the original drug Nintedanib (Nintedanib) is marketed in the form of nintedanib ethanesulfonate soft capsules, with the trade name OFev, and has been included in the scope of Class B medical insurance. Medical insurance coverage is premised on patients meeting specific indications, such as being diagnosed with pulmonary fibrosis caused by idiopathic pulmonary fibrosis (IPF) or other interstitial lung diseases. For non-indicated patients, they need to bear the cost of the medicine themselves. Nintedanib is usually administered in oral capsule form in clinical practice, with common specifications including 100 mg × 30 capsules and 150 mg × 30 capsules. According to market circulation conditions, the domestic price in 2025 will be approximately more than 4,000 yuan per box. The actual payment amount may vary due to medical insurance reimbursement ratios and regional differences.

The selling price of nintedanib in overseas markets varies greatly depending on the country and manufacturer. European and American versions of original drugs are usually more expensive, while generic drugs are also available in some Asian countries or regions. Generic drugs are consistent with the original drugs in terms of ingredients and efficacy, but at a lower price, providing patients with an economically viable option. However, in mainland China, original drugs are still officially listed and covered by medical insurance.
Medical insurance reimbursement policies have a significant impact on patients’ medication burden. When covered by Class B medical insurance, eligible patients can be reimbursed for drug costs according to the prescribed proportion, thereby reducing the burden of treatment. Before using nintedanib, patients should consult their hospital or pharmacy to learn about the specific reimbursement ratio, minimum payment standard and reimbursement process, so as to reasonably plan long-term treatment costs.
In addition to price factors, patients should consider the importance of side effect management, dose compliance, and regular follow-up when using nintedanib. Rational drug use not only helps reduce the rate of disease progression, but also ensures maximum drug efficacy. Especially for chronic progressive diseases such as pulmonary fibrosis, long-term continuous drug use is the key to maintaining lung function.
Reference materials:https://en.wikipedia.org/wiki/Nintedanib
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)